$MC

UBS upgrades Moelis stock rating to neutral on valuation reset

UBS upgraded Moelis & Company (MC) to Neutral from Sell, lowering its price target to $59. The bank cited a reset in stock valuation and a challenging M&A backdrop, particularly in sponsor activity. Moelis's Q2 2026 earnings beat expectations, with $0.63 EPS on $409.4M revenue, a 12% year-over-year increase. The company faces challenges related to Saudi Arabia's regional headquarters requirements.

Original reporting
Published Oct 7, 2026, 7:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MC
Neutral
high confidence
Mentioned
$MC
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MCNeutralLow
01

Why it matters

The upgrade provides a new data point for traders; the modest target cut may trigger short‑term selling pressure.

02

Market read

Analyst rating change is the primary actionable element; earnings figures are historical and not new.

03

What to watch

Potential upside from Moelis's tech franchise investments and any unexpected surge in sponsor deals could offset the rating downgrade.

Relevance 6/10Novelty 5/10Timing: today

Background

The article recaps Moelis's Q2 2026 earnings (already released) and adds UBS's fresh analyst upgrade to Neutral with a slight target reduction.

Company-level read

Ticker impact

$MCNeutralHigh confidence
Context

UBS upgraded Moelis & Co. to Neutral and cut its price target to $59, citing a valuation reset and softer deal pipeline.

Expected impact

likely modest pressure as the market prices in the reduced target and neutral stance

Evidence & confidence

Analyst downgrade is a fresh catalyst; the modest target cut signals weaker expectations, which typically weighs on the stock.

Market effects

M&A advisory sector may face scrutiny as sponsor activity is expected to stay weak through 2027.

Limited to U.S. investment banking and advisory firms.

Minor; primarily affects Moelis and peers tracking sponsor‑driven deal flow.

Counterpoint

Some investors may view the neutral rating as a buying opportunity if they believe sponsor activity will rebound faster than UBS expects.

Key entities

  • Moelis & Company

    Investment bank providing advisory services.

  • UBS

    Equity research firm issuing the rating change.

Related articles

$PJTMed

Investment Banking & Brokerage Stocks Q2 In Review: PJT (NYSE:PJT) Vs Peers

Perella Weinberg (PJT) reported flat revenue of $156.5M, beating EPS estimates, with stock up 7.1%. Houlihan Lokey (HLI) saw revenue drop 15.6% to $511M, missing estimates, with stock down 8%. Goldman Sachs (GS) reported $20.34B revenue, up 39.5%, beating estimates, but stock down 4%. Moelis (MC) reported $409.4M revenue, up 12%, beating estimates, with stock up 2.5%.

$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.